01572nam a2200253 a 450000100080000000500110000800800410001910000140006024502640007426001520033852005980049065000220108865000170111065000230112765000160115065300220116670000210118870000130120970000220122270000200124470000190126470000180128370000170130121466582022-09-20       2022    bl uuuu     u00u1 u    #d1 aHAACH, V.  aCellular and humoral immunity elicited by an Influenza A polyvalent virosomal vaccine in pigs. InbINTERNATIONAL PIG VETERINARY SOCIETY CONGRESS, 26., 2022, Rio de Janeiro. Proceedings... Rio de Janeiro, RJ: IPVS: Abraves, 2022. p. 421.h[electronic resource]  aIn: INTERNATIONAL PIG VETERINARY SOCIETY CONGRESS, 26., 2022, Rio de Janeiro. Proceedings... Rio de Janeiro, RJ: IPVS: Abraves, 2022. p. 421.c2022  aInfluenza A virus (IAV) causes economic losses to the swine industry and public health concerns. The IAV is endemic in pigs and genetically and antigenically distinct virus lineages of subtypes H1N1, H1N2 and H3N2 circulate in different geographic regions with limited cross-protection (1, 2). The co-circulation of distinct IAV lineages associated with rapid viral evolution challenges the development of effective vaccines. The aim of this study was to evaluate the immunogenicity of an adjuvanted virosome-based influenza vaccine containing the hemagglutinin (HA) of H1N1pdm, H1N2 and H3N2.  aInfluenza A virus  aSuinocultura  aVacina Polivalente  aVacinação  aImunidade celular1 aBASTOS, A. P. A.1 aGAVA, D.1 aFONSECA, F. M. da1 aMORES, M. A. Z.1 aCOLDEBELLA, A.1 aFRANCO, A. C.1 aSCHAEFER, R.